CTOs on the Move

Kiniksa Pharmaceuticals

www.kiniksa.com

 
Our Story Kiniksa’s goal is to build a fully-integrated biopharmaceutical company. Our management team and employees are focused on advancing a portfolio of immune-modulating, clinical-stage product candidates that target underserved conditions and off...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kiniksa.com
  • 100, Hayden Ave
    Lexington, MA USA 02421
  • Phone: 781.431.9100

Executives

Name Title Contact Details

Similar Companies

Family Dental

Family Dental is a Haverhill, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Recombinetics

Recombinetics is a global leader in proprietary gene repair and gene-editing technology. Our breakthrough scientific research and development of TALEN and CRISPR (Cas9) gene editing technologies has resulted in breakthroughs in the regenerative medicine, disease research and animal agriculture.

Kirkegaard and Perry Laboratories

KPL is committed to protecting the privacy of our customers. Our Privacy Policy covers any personal information that KPL.com obtains from you when you use services on our site. We use this information to enhance our services and to make them more

Mana Therapeutics

MANA was founded in November 2018, based on the research and human proof-of-concept clinical trials conducted by Dr. Catherine Bollard and her team at Children`s National Hospital (CNH) in Washington, D.C., along with colleagues at Johns Hopkins Medical Center.

Pneuma Respiratory

Founded in 2015, Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD. Pneuma is leveraging more than three decades of healthcare research and product development experience along with hand held device design and manufacturing expertise.